Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
Claim Your Discount
Claim MarketBeat All Access Sale Promotion

RUA Life Sciences (RUA) Competitors

RUA Life Sciences logo
GBX 24 +0.64 (+2.74%)
As of 05/18/2026 12:32 PM Eastern
Compare

RUA vs. IUG, IHC, NCYT, AVO, and MHC

Should you buy RUA Life Sciences stock or one of its competitors? MarketBeat compares RUA Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with RUA Life Sciences include Intelligent Ultrasound Group (IUG), Inspiration Healthcare Group (IHC), Novacyt (NCYT), Advanced Oncotherapy (AVO), and MyHealthChecked (MHC). These companies are all part of the "medical devices" industry.

How does RUA Life Sciences compare to Intelligent Ultrasound Group?

RUA Life Sciences (LON:RUA) and Intelligent Ultrasound Group (LON:IUG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

RUA Life Sciences has a net margin of -3.26% compared to Intelligent Ultrasound Group's net margin of -23.11%. RUA Life Sciences' return on equity of -2.03% beat Intelligent Ultrasound Group's return on equity.

Company Net Margins Return on Equity Return on Assets
RUA Life Sciences-3.26% -2.03% -17.50%
Intelligent Ultrasound Group -23.11%-23.58%-13.51%

Intelligent Ultrasound Group has higher revenue and earnings than RUA Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RUA Life Sciences£4.11M3.62-£2.66MN/AN/A
Intelligent Ultrasound Group£6.57M0.00-£2.27M-£0.68N/A

RUA Life Sciences has a beta of 0.968, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Intelligent Ultrasound Group has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

In the previous week, RUA Life Sciences' average media sentiment score of 0.00 equaled Intelligent Ultrasound Group'saverage media sentiment score.

Company Overall Sentiment
RUA Life Sciences Neutral
Intelligent Ultrasound Group Neutral

0.1% of RUA Life Sciences shares are owned by institutional investors. Comparatively, 75.5% of Intelligent Ultrasound Group shares are owned by institutional investors. 7.3% of RUA Life Sciences shares are owned by company insiders. Comparatively, 12.8% of Intelligent Ultrasound Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Intelligent Ultrasound Group beats RUA Life Sciences on 5 of the 9 factors compared between the two stocks.

How does RUA Life Sciences compare to Inspiration Healthcare Group?

Inspiration Healthcare Group (LON:IHC) and RUA Life Sciences (LON:RUA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

8.2% of Inspiration Healthcare Group shares are owned by institutional investors. Comparatively, 0.1% of RUA Life Sciences shares are owned by institutional investors. 8.4% of Inspiration Healthcare Group shares are owned by insiders. Comparatively, 7.3% of RUA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

RUA Life Sciences has a net margin of -3.26% compared to Inspiration Healthcare Group's net margin of -25.32%. RUA Life Sciences' return on equity of -2.03% beat Inspiration Healthcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Inspiration Healthcare Group-25.32% -69.35% -3.47%
RUA Life Sciences -3.26%-2.03%-17.50%

In the previous week, Inspiration Healthcare Group's average media sentiment score of 0.00 equaled RUA Life Sciences'average media sentiment score.

Company Overall Sentiment
Inspiration Healthcare Group Neutral
RUA Life Sciences Neutral

Inspiration Healthcare Group has a beta of 0.717, indicating that its stock price is 28% less volatile than the broader market. Comparatively, RUA Life Sciences has a beta of 0.968, indicating that its stock price is 3% less volatile than the broader market.

RUA Life Sciences has lower revenue, but higher earnings than Inspiration Healthcare Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inspiration Healthcare Group£45.20M0.59-£12.20M-£13.65N/A
RUA Life Sciences£4.11M3.62-£2.66MN/AN/A

Summary

Inspiration Healthcare Group and RUA Life Sciences tied by winning 5 of the 10 factors compared between the two stocks.

How does RUA Life Sciences compare to Novacyt?

Novacyt (LON:NCYT) and RUA Life Sciences (LON:RUA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

RUA Life Sciences has lower revenue, but higher earnings than Novacyt.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt£20.03M1.66-£36.80M-£43.00N/A
RUA Life Sciences£4.11M3.62-£2.66MN/AN/A

In the previous week, Novacyt's average media sentiment score of 0.00 equaled RUA Life Sciences'average media sentiment score.

Company Overall Sentiment
Novacyt Neutral
RUA Life Sciences Neutral

RUA Life Sciences has a net margin of -3.26% compared to Novacyt's net margin of -135.96%. RUA Life Sciences' return on equity of -2.03% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Novacyt-135.96% -111.34% -27.98%
RUA Life Sciences -3.26%-2.03%-17.50%

10.7% of Novacyt shares are held by institutional investors. Comparatively, 0.1% of RUA Life Sciences shares are held by institutional investors. 0.5% of Novacyt shares are held by insiders. Comparatively, 7.3% of RUA Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Novacyt has a beta of 0.973, meaning that its share price is 3% less volatile than the broader market. Comparatively, RUA Life Sciences has a beta of 0.968, meaning that its share price is 3% less volatile than the broader market.

Summary

RUA Life Sciences beats Novacyt on 6 of the 10 factors compared between the two stocks.

How does RUA Life Sciences compare to Advanced Oncotherapy?

RUA Life Sciences (LON:RUA) and Advanced Oncotherapy (LON:AVO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

RUA Life Sciences has a beta of 0.968, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Advanced Oncotherapy has a beta of 0.06, meaning that its stock price is 94% less volatile than the broader market.

RUA Life Sciences has higher revenue and earnings than Advanced Oncotherapy.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RUA Life Sciences£4.11M3.62-£2.66MN/AN/A
Advanced OncotherapyN/AN/A-£32.60M-£0.07N/A

0.1% of RUA Life Sciences shares are held by institutional investors. Comparatively, 17.8% of Advanced Oncotherapy shares are held by institutional investors. 7.3% of RUA Life Sciences shares are held by insiders. Comparatively, 47.5% of Advanced Oncotherapy shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, RUA Life Sciences' average media sentiment score of 0.00 equaled Advanced Oncotherapy'saverage media sentiment score.

Company Overall Sentiment
RUA Life Sciences Neutral
Advanced Oncotherapy Neutral

Advanced Oncotherapy has a net margin of 0.00% compared to RUA Life Sciences' net margin of -3.26%. RUA Life Sciences' return on equity of -2.03% beat Advanced Oncotherapy's return on equity.

Company Net Margins Return on Equity Return on Assets
RUA Life Sciences-3.26% -2.03% -17.50%
Advanced Oncotherapy N/A -67.34%-11.73%

Summary

RUA Life Sciences beats Advanced Oncotherapy on 5 of the 9 factors compared between the two stocks.

How does RUA Life Sciences compare to MyHealthChecked?

MyHealthChecked (LON:MHC) and RUA Life Sciences (LON:RUA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

MyHealthChecked has higher earnings, but lower revenue than RUA Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MyHealthChecked£3.22M1.48-£1.04M-£3.76N/A
RUA Life Sciences£4.11M3.62-£2.66MN/AN/A

0.7% of MyHealthChecked shares are held by institutional investors. Comparatively, 0.1% of RUA Life Sciences shares are held by institutional investors. 9.3% of MyHealthChecked shares are held by company insiders. Comparatively, 7.3% of RUA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, MyHealthChecked's average media sentiment score of 0.00 equaled RUA Life Sciences'average media sentiment score.

Company Overall Sentiment
MyHealthChecked Neutral
RUA Life Sciences Neutral

RUA Life Sciences has a net margin of -3.26% compared to MyHealthChecked's net margin of -60.34%. RUA Life Sciences' return on equity of -2.03% beat MyHealthChecked's return on equity.

Company Net Margins Return on Equity Return on Assets
MyHealthChecked-60.34% -30.82% -8.18%
RUA Life Sciences -3.26%-2.03%-17.50%

MyHealthChecked has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market. Comparatively, RUA Life Sciences has a beta of 0.968, suggesting that its share price is 3% less volatile than the broader market.

Summary

MyHealthChecked beats RUA Life Sciences on 6 of the 10 factors compared between the two stocks.

Get RUA Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for RUA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RUA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RUA vs. The Competition

Export
MetricRUA Life SciencesMedical Devices IndustryMedical SectorLON Exchange
Market Cap£14.89M£2.07B£6.25B£2.76B
Dividend Yield1.44%2.67%2.80%6.15%
P/E Ratio-2.6113.9220.86365.85
Price / Sales3.62129.89550.9188,116.34
Price / Cash2.4015.9927.4827.89
Price / Book1.124.569.677.62
Net Income-£2.66M£144.75M£3.56B£5.89B
7 Day Performance-4.84%-1.30%-1.69%0.42%
1 Month Performance34.30%0.96%-2.65%0.56%
1 Year Performance111.77%7.52%30.03%84.41%

RUA Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RUA
RUA Life Sciences
N/AGBX 24
+2.7%		N/A+102.1%£14.89M£4.11MN/A48
IUG
Intelligent Ultrasound Group
N/AN/AN/AN/A£42.76M£6.57MN/A65
IHC
Inspiration Healthcare Group
N/AGBX 30.60
+3.4%		N/A+50.1%£27.44M£45.20MN/A224
NCYT
Novacyt
N/AGBX 28
+5.3%		N/A+18.9%£20.29M£19.45MN/A120
AVO
Advanced Oncotherapy
N/AN/AN/AN/A£9.50MN/AN/A3,900

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:RUA) was last updated on 5/19/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Is the SpaceX IPO “Rigged?”
The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...
The Oxford Club | Sponsoredtc pixel